相关实验视频

Updated: Jul 15, 2025

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

Flt3激活通过重新平衡的L-OPA1处理来缓解线粒体碎片和心脏功能障碍,通过阻碍心脏重塑中的乙化p53和PHB2之间的相互作用来缓解线粒体碎片化和心脏功能障碍

Kaina Zhang^1,2, Yeqing Zheng^1,2, Gaowa Bao^1,2

¹Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710061, China.

Antioxidants (Basel, Switzerland)

|September 28, 2023

概括

与FMS类似的氨酸激酶3 (Flt3) 激活通过减少线粒体碎片化来保护心脏. 它通过抑制乙化-p53来实现这一目标.

科学领域:

心血管生物学心血管生物学
线粒体动力学的动力学
分子机制的分子机制

背景情况:

心脏不适应性重塑是一个重要的临床问题.
与FMS相似的氨酸激酶3 (Flt3) 在缓解心脏重塑方面表现有前途.
在心脏压力下的线粒体动态中Flt3的确切作用尚不清楚.

研究的目的:

阐明Flt3调节p53介导的光缩1 (OPA1) 处理的机制.
调查Flt3在预防心脏压力期间线粒体碎片化的作用.
了解Flt3激活如何改善心脏重塑.

主要方法:

在心肌细胞中诱导线粒体碎片化,使用异上腺素 (ISO) 和H2O2 in vitro.
在小鼠中通过冠状动脉绑定或慢性ISO挑战 in vivo建立心脏重塑.
分析蛋白相互作用,乙化和表达水平,包括p53,PHB2和OPA1.1.

主要成果:

心脏压力增加了线粒体乙化-p53 (ac-p53),促进了OPA1降解和线粒体碎片化.
Flt3激活通过SIRT1降低了线粒体ac-p53,稳定了OPA1并抑制了碎片化.
一个无法结合PHB2的p53突变阻止了这些压力诱导的效应.

结论:

通过减少线粒体碎片化,flt3激活减轻了心脏不适应性重塑.
该机制涉及Flt3介导的ac-p53的减少,从而保持OPA1的稳定性.
这一途径突出了涉及线粒体功能障碍的心脏病的新型治疗点.

关键词:

类似FMS的受体氨酸激酶3 在OPA1中,OPA1是OPA1.进行心脏重塑.线粒体动力学不平衡的失衡在 p53 里,p53 是一个 p53 的类型.禁止了这些物质.

更多相关视频

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

相关概念视频

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...